Efficacy and Safety Study of Neramexane to Treat Congenital and Acquired Nystagmus

Merz Pharmaceuticals logo

Merz Pharmaceuticals

Status and phase

Completed
Phase 2

Conditions

Nystagmus, Congenital Idiopathic
Nystagmus, Acquired

Treatments

Drug: Neramexane mesylate

Study type

Interventional

Funder types

Industry

Identifiers

NCT00661440
MRZ 92579-0707/1
EudraCT Number 2007-002595-34

Details and patient eligibility

About

The purpose of this study is to investigate the safety and efficacy of neramexane mesylate in the treatment of congenital idiopathic nystagmus (CIN) in comparison to placebo. In addition, a subgroup of multiple sclerosis (MS) patients suffering from acquired nystagmus will be included; this subgroup will be analyzed in an exploratory manner only.

Enrollment

48 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • patients with congenital idiopathic nystagmus or acquired nystagmus subsequent to multiple sclerosis
  • male or female outpatients
  • aged between 18 and 80 years (inclusive) at screening

Exclusion criteria

patients with evidence of neurologic disorders other than CIN such as congenital nystagmus due to albinism or retinal diseases and/or acquired nystagmus (exemption: secondary to MS)

Trial design

48 participants in 2 patient groups

1
Other group
Treatment:
Drug: Neramexane mesylate
2
Other group
Treatment:
Drug: Neramexane mesylate

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems